

Selina Tsim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8359828/publications.pdf>

Version: 2024-02-01

18
papers

796
citations

840119

11
h-index

839053

18
g-index

18
all docs

18
docs citations

18
times ranked

972
citing authors

#	ARTICLE	IF	CITATIONS
1	Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. <i>European Respiratory Review</i> , 2016, 25, 472-486.	3.0	225
2	British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. <i>Thorax</i> , 2018, 73, i1-i30.	2.7	157
3	Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000240.	1.2	132
4	The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. <i>Lung Cancer</i> , 2017, 103, 38-43.	0.9	40
5	Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2016, 101, 48-58.	0.9	38
6	BTS guideline for the investigation and management of malignant pleural mesothelioma. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000266.	1.2	35
7	Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. <i>BMJ Open</i> , 2016, 6, e013324.	0.8	29
8	Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy. <i>Lung Cancer</i> , 2018, 118, 48-56.	0.9	26
9	Pre-EDIT. <i>Chest</i> , 2019, 156, 1204-1213.	0.4	22
10	Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy – Data supporting – Direct to LAT™ in selected groups. <i>Lung Cancer</i> , 2019, 133, 123-129.	0.9	20
11	Inter-observer variation in image interpretation and the prognostic importance of non-expansile lung in malignant pleural effusion. <i>Respirology</i> , 2020, 25, 298-304.	1.3	15
12	Chest drain aerosol generation in COVID-19 and emission reduction using a simple anti-viral filter. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000710.	1.2	12
13	A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. <i>Lung Cancer</i> , 2020, 150, 12-20.	0.9	11
14	Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1705-1717.	0.5	10
15	Intrapleural Fibrinolytics and Deoxyribonuclease for Treatment of Indwelling Pleural Catheter-Related Pleural Infection: A Multi-Center Observational Study. <i>Respiration</i> , 2021, 100, 452-460.	1.2	9
16	Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. <i>Thorax</i> , 2022, , thoraxjnl-2021-217808.	2.7	6
17	Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000293.	1.2	5
18	Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial). <i>BMJ Open Respiratory Research</i> , 2021, 8, e000846.	1.2	4